Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiome Oxyprim “Approvable” For Gout, But Product’s Future Now In Doubt

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA requests additional clinical and manufacturing data. Cardiome will “reflect” on FDA’s comments before making a final decision on oxypurinol.

You may also be interested in...



Cardiome Expects Anti-Arrhythmic NDA Submission By 2006

In a Phase III study, 52% of patients with recent onset atrial fibrillation converted to normal heart rhythm compared to 4% for placebo. RSD1235 could merit premium pricing over Wyeth’s Cordarone and amiodarone generics, Cardiome CEO says.

Cardiome Expects Anti-Arrhythmic NDA Submission By 2006

In a Phase III study, 52% of patients with recent onset atrial fibrillation converted to normal heart rhythm compared to 4% for placebo. RSD1235 could merit premium pricing over Wyeth’s Cordarone and amiodarone generics, Cardiome CEO says.

Cardiome Oxyprim, Chronic Gout Drug Trials May Use Surrogate Endpoints For Approval, Cmte. Says

Surrogate endpoint should seek a reduction in serum uric acid to a level of 6 mg/dL. Clinical outcome trials to confirm benefits of chronic gout products through reduction in gouty attacks should be carried out post-approval.

Topics

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel